GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (XTER:5CV) » Definitions » Sale Of Business

CureVac NV (XTER:5CV) Sale Of Business : €0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Sale Of Business?

CureVac NV's sale of business for the three months ended in Dec. 2024 was €0.0 Mil. It means CureVac NV gained €0.0 Mil from selling business. CureVac NV's sale of business for the trailing twelve months (TTM) ended in Dec. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Sep. 2024 ), CureVac NV gained the same money from selling business in Dec. 2024 (€0.0 Mil).


CureVac NV Sale Of Business Historical Data

The historical data trend for CureVac NV's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Sale Of Business Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Business
Get a 7-Day Free Trial - - - - -

CureVac NV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CureVac NV Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV Sale Of Business Related Terms

Thank you for viewing the detailed overview of CureVac NV's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV Headlines

No Headlines